Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William E Carson

Showing results (41-50 of 272) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 YearsBarbara L Andersen, Neha Godiwala Goyal, Travis D Westbrook, et al.
Cancer Immunology, Immunotherapy : CII|April 28, 2009
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cellsGregory B Lesinski, Kristen Benninger, Melanie Kreiner, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2007
STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alphaJason M Zimmerer, Gregory B Lesinski, Michael D Radmacher, et al.
Oncoimmunology|November 22, 2012
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivoKevin C Foy, Megan J Miller, Nicanor Moldovan, et al.
Biomedical Microdevices|April 19, 2005
Release of biologically functional interferon-alpha from a nanochannel delivery systemGregory B Lesinski, Sadhana Sharma, Kimberly A Varker, et al.
Oncoimmunology|March 13, 2013
Correction to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048-1060Kevin C Foy, Megan J Miller, Nicanor Moldovan, et al.
Frontiers in Cell and Developmental Biology|October 25, 2021
CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of MelanomaFatemeh Talebian, Jianyu Yu, Kimberly Lynch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Cellular immunity in breast cancer patients completing taxane treatmentWilliam E Carson, Charles L Shapiro, Timothy R Crespin, et al.
Cancer Research|January 7, 2006
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cellsJulie M Roda, Robin Parihar, Cynthia Magro, et al.
Cancer|June 4, 2008
Delayed emotional recovery after taxane-based chemotherapyLisa M Thornton, William E Carson, Charles L Shapiro, et al.
Pageof 28

Showing results (41-50 of 272) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 YearsBarbara L Andersen, Neha Godiwala Goyal, Travis D Westbrook, et al.
Cancer Immunology, Immunotherapy : CII|April 28, 2009
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cellsGregory B Lesinski, Kristen Benninger, Melanie Kreiner, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2007
STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alphaJason M Zimmerer, Gregory B Lesinski, Michael D Radmacher, et al.
Oncoimmunology|November 22, 2012
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivoKevin C Foy, Megan J Miller, Nicanor Moldovan, et al.
Biomedical Microdevices|April 19, 2005
Release of biologically functional interferon-alpha from a nanochannel delivery systemGregory B Lesinski, Sadhana Sharma, Kimberly A Varker, et al.
Oncoimmunology|March 13, 2013
Correction to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048-1060Kevin C Foy, Megan J Miller, Nicanor Moldovan, et al.
Frontiers in Cell and Developmental Biology|October 25, 2021
CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of MelanomaFatemeh Talebian, Jianyu Yu, Kimberly Lynch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Cellular immunity in breast cancer patients completing taxane treatmentWilliam E Carson, Charles L Shapiro, Timothy R Crespin, et al.
Cancer Research|January 7, 2006
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cellsJulie M Roda, Robin Parihar, Cynthia Magro, et al.
Cancer|June 4, 2008
Delayed emotional recovery after taxane-based chemotherapyLisa M Thornton, William E Carson, Charles L Shapiro, et al.
Pageof 28